Cephalexin Anhydrous

CHEMBL1727 Phase 4 अनुमोदित Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
347.4 g/mol
LogP
0.6
Phase
4

The anhydrous form of cephalexin is a first-generation oral cephalosporin equivalent in antibacterial activity to the standard formulation. It is used for common bacterial infections including skin, urinary, and respiratory infections caused by susceptible organisms. The anhydrous form simply lacks the water of crystallization present in some preparations.

आणविक भार

347.4000 g/mol

LogP

0.60

TPSA

138.00 Ų

लिपिंस्की RO5

उत्तीर्ण

क्रिया का तंत्र

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

तंत्र

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

2D संरचना

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1

InChI

InChI=1S/C16H17N3O4S/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9/h2-6,10-11,15H,7,17H2,1H3,(H,18,20)(H,22,23)/t10-,11-,15-/m1/s1

Molecular Formula

C16H17N3O4S

HBD / HBA

3 / 6

घूर्णनीय बंधन

4

भारी परमाणु

24

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

अक्सर पूछे जाने वाले प्रश्न

The anhydrous form of cephalexin is a first-generation oral cephalosporin equivalent in antibacterial activity to the standard formulation. It is used for common bacterial infections including skin, urinary, and respiratory infections caused by susceptible organisms. The anhydrous form simply lacks the water of crystallization present in some preparations.

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Yes, Cephalexin Anhydrous is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1727. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 27447. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

चिकित्सा अस्वीकरण

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.